🇺🇸 FDA
Patent

US 12172969

Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof

granted A61KA61K31/4164A61K31/565

Quick answer

US patent 12172969 (Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof) held by EVOFEM BIOSCIENCES, INC. expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
EVOFEM BIOSCIENCES, INC.
Grant date
Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/4164, A61K31/565, A61K31/567, A61K31/57